Paracetamol and Ibuprofen and Morphine Consumption After Total Hip Arthroplasty | Orthopedics | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Combination of Paracetamol (Acetaminophen) and Ibuprofen vs Either Alone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip ArthroplastyThe PANSAID Randomized Clinical Trial

Educational Objective
To review if paracetamol (acetaminophen) combined with ibuprofen reduce postoperative morphine usage
1 Credit CME
Key Points

Question  Does paracetamol (acetaminophen) combined with ibuprofen reduce postoperative morphine usage relative to the use of each drug alone in patients undergoing total hip arthroplasty (THA), and does ibuprofen increase the incidence of serious adverse events (SAEs)?

Findings  In this randomized clinical trial that included 556 patients who underwent THA, morphine usage in the first 24 hours was statistically significantly lower for the combination of paracetamol 1000 mg and ibuprofen 400 mg than for either alone; however, the combined medications did not meet the prespecified threshold for clinically important postoperative morphine reduction (10 mg) compared with ibuprofen alone. The percentage of patients with SAEs for those in any of the ibuprofen groups vs paracetamol alone was 15% vs 11%, which was not statistically significant.

Meaning  Although the combined use of paracetamol and ibuprofen reduced immediate postoperative morphine consumption compared with paracetamol alone in patients undergoing THA, ibuprofen alone resulted in comparable pain control without increasing SAEs, suggesting that ibuprofen alone may be a reasonable option.

Abstract

Importance  Multimodal postoperative analgesia is widely used but lacks evidence of benefit.

Objective  Investigate beneficial and harmful effects of 4 nonopioid analgesics regimens.

Design, Setting, and Participants  Randomized, blinded, placebo-controlled, 4-group trial in 6 Danish hospitals with 90-day follow-up that included 556 patients undergoing total hip arthroplasty (THA) from December 2015 to October 2017. Final date of follow-up was January 1, 2018.

Interventions  Participants were randomized to receive paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (n = 136; PCM + IBU), paracetamol 1000 mg plus matched placebo (n = 142; PCM), ibuprofen 400 mg plus matched placebo (n = 141; IBU), or half-strength paracetamol 500 mg plus ibuprofen 200 mg (n = 140; HS–PCM + IBU) orally every 6 hours for 24 hours postoperatively, starting 1 hour before surgery.

Main Outcomes and Measures  Two co–primary outcomes: 24-hour morphine consumption using patient-controlled analgesia in pairwise comparisons between the 4 groups (multiplicity-adjusted thresholds for statistical significance, P < .0042; minimal clinically important difference, 10 mg), and proportion of patients with 1 or more serious adverse events (SAEs) within 90 days (multiplicity-adjusted thresholds for statistical significance, P < .025).

Results  Among 559 randomized participants (mean age, 67 years; 277 [50%] women), 556 (99.5%) completed the trial and were included in the analysis. Median 24-hour morphine consumption was 20 mg (99.6% CI, 0-148) in the PCM + IBU group, 36 mg (99.6% CI, 0-166) for PCM alone, 26 mg (99.6% CI, 2-139) for IBU alone, and 28 mg (99.6% CI, 2-145) for HS–PCM + IBU. The median difference in morphine consumption between the PCM + IBU group vs PCM alone was 16 mg (99.6% CI, 6.5 to 24; P < .001); for the PCM-alone group vs HS–PCM + IBU, 8 mg (99.6% CI, −1 to 14; P = .001); and for the PCM + IBU group vs IBU alone, 6 mg (99.6% CI, −2 to 16; P = .002). The difference in morphine consumption was not statistically significant for the PCM + IBU group vs HS–PCM + IBU (8 mg [99.6% CI, −2 to 16]; P = .005) or for the PCM-alone group vs IBU alone (10 mg [99.6% CI, −2 to 16]; P = .004) after adjustment for multiple comparisons and 2 co–primary outcomes. There was no significant difference between the IBU-alone group vs HS–PCM + IBU (2 mg [99.6% CI, −10 to 7]; P = .81). The proportion of patients with SAEs in groups receiving IBU was 15%, and in the PCM-alone group, was 11%. The relative risk of SAE was 1.44 (97.5% CI, 0.79 to 2.64; P = .18).

Conclusions and Relevance  Among patients undergoing THA, paracetamol plus ibuprofen significantly reduced morphine consumption compared with paracetamol alone in the first 24 hours after surgery; there was no statistically significant increase in SAEs in the pooled groups receiving ibuprofen alone vs with paracetamol alone. However, the combination did not result in a clinically important improvement over ibuprofen alone, suggesting that ibuprofen alone may be a reasonable option for early postoperative oral analgesia.

Trial Registration  ClinicalTrials.gov Identifier: NCT02571361

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Kasper Højgaard Thybo, MD, Department of Anesthesiology, Næstved Hospital, Ringstedgade 61, 4700 Næstved, Denmark (khty@regionsjealland.dk).

Accepted for Publication: December 26, 2018.

Author Contributions: Dr Thybo had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Thybo and Hägi-Pedersen contributed equally to this article. Dr Mathiesen was senior author.

Concept and design: Thybo, Hägi-Pedersen, Dahl, Wetterslev, Mathiesen.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Thybo, Hägi-Pedersen, Dahl, Wetterslev, Skovmand, Mathiesen.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Thybo, Wetterslev, Jakobsen.

Obtained funding: Thybo, Dahl.

Administrative, technical, or material support: Thybo, Jakobsen, Overgaard, Schrøder, Bjørck, Skovmand, Frederiksen, Buus-Nielsen, Sørensen, Kruuse, Lindholm.

Supervision: Thybo, Hägi-Pedersen, Dahl, Pedersen, Overgaard, Bjørck, Skovmand, Lindholm, Mathiesen.

Other - Recruitment of participants and collection of data: Nersesjan.

Conflict of Interest Disclosures: Dr Thybo reported grants from the following: the Danish Society of Anaesthesiology and Intensive Care Medicine (DASAIM), Sophus Johansens Fund, Region Zealand Health Scientific Research Foundation, the local research foundation at Næstved-Slagelse-Ringsted Hospitals, the A.P. Møller Foundation for the Advancement of Medical Science, Aase og Ejnar Danielsens Fund, and the Grosserer Christian Andersen og Hustru Ingeborg Andersen, f. Schmidts legat (fund) during the conduct of the study; and was employed as a doctoral student while he was primary investigator of this trial. Dr Overgaard reported grants from Biomet Denmark, Biomet Inc, DePuy and Protesekompagniet, and Zimmer; serving as an investigator for Sanofi-Aventis Denmark A/S; and serving on an advisory board for Eli Lilly and Multipharma International Ltd outside the submitted work. No other disclosures were reported.

Funding/Support: Funding was provided by DASAIM, Sophus Johansens Fond, Region Zealand Health Scientific Research Foundation, the local research foundation at Næstved-Slagelse-Ringsted Hospitals, the A.P. Møller Foundation for the Advancement of Medical Science, Aase og Ejnar Danielsens Fond, and the Grosserer Christian Andersen og Hustru Ingeborg Andersen, f. Schmidts legat (fund).

Role of the Funder/Sponsor: None of the funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We wish to thank patients, relatives, and clinical and research staff at all trial sites. We give thanks to monitors for their excellent cooperation, in particular Birgitte Grøn, PhD, and Pernille Ask Aabo, MScPharm, at the Good Clinical Practice (GCP) unit at Copenhagen University Hospital, and Henriette Kunch Bendixen, MScPharm, at the GCP unit at Odense University Hospital. We also wish to thank Janus Engstrøm, BSc, at Copenhagen trial unit for creating and maintaining the trial database and creating the randomization list and allocation system. Finally, we wish to thank the Pharmacy of the Capital Region, Herlev for masking the trial medicine. Neither Grøn, Aabo, Bendixen, nor Engstrøm received personal compensation for their role in the trial.

Compensation for the Role in the Trial: The Copenhagen Trial Unit was paid for randomization and the electronic case report form. The GCP unit was compensated for monitoring the trial according to Danish law.

References
1.
Wick  EC, Grant  MC, Wu  CL.  Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review.  JAMA Surg. 2017;152(7):691-697. doi:10.1001/jamasurg.2017.0898PubMedGoogle Scholar
2.
Wu  CL, Raja  SN.  Treatment of acute postoperative pain.  Lancet. 2011;377(9784):2215-2225. doi:10.1016/S0140-6736(11)60245-6PubMedGoogle Scholar
3.
Maund  E, McDaid  C, Rice  S, Wright  K, Jenkins  B, Woolacott  N.  Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review.  Br J Anaesth. 2011;106(3):292-297. doi:10.1093/bja/aeq406PubMedGoogle Scholar
4.
De Oliveira  GS  Jr, Castro-Alves  LJ, McCarthy  RJ.  Single-dose systemic acetaminophen to prevent postoperative pain: a meta-analysis of randomized controlled trials.  Clin J Pain. 2015;31(1):86-93. doi:10.1097/AJP.0000000000000081PubMedGoogle Scholar
5.
McNicol  ED, Ferguson  MC, Haroutounian  S, Carr  DB, Schumann  R.  Single dose intravenous paracetamol or intravenous propacetamol for postoperative pain.  Cochrane Database Syst Rev. 2016;(5):CD007126.PubMedGoogle Scholar
6.
Dahl  JB, Nielsen  RV, Wetterslev  J,  et al; Scandinavian Postoperative Pain Alliance (ScaPAlli).  Post-operative analgesic effects of paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review.  Acta Anaesthesiol Scand. 2014;58(10):1165-1181. doi:10.1111/aas.12382PubMedGoogle Scholar
7.
Mathiesen  O, Wetterslev  J, Kontinen  VK,  et al; Scandinavian Postoperative Pain Alliance (ScaPAlli).  Adverse effects of perioperative paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review.  Acta Anaesthesiol Scand. 2014;58(10):1182-1198. doi:10.1111/aas.12380PubMedGoogle Scholar
8.
Rawal  N.  Current issues in postoperative pain management.  Eur J Anaesthesiol. 2016;33(3):160-171. doi:10.1097/EJA.0000000000000366PubMedGoogle Scholar
9.
Hansen  MS, Petersen  EE, Dahl  JB, Wetterslev  J.  Post-operative serious adverse events in a mixed surgical population—a retrospective register study.  Acta Anaesthesiol Scand. 2016;60(9):1209-1221. doi:10.1111/aas.12762PubMedGoogle Scholar
10.
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators; Devereaux  PJ, Chan  MT, Alonso-Coello  P,  et al.  Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery.  JAMA. 2012;307(21):2295-2304. doi:10.1001/jama.2012.5502PubMedGoogle Scholar
11.
Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala  N, Emberson  J, Merhi  A,  et al.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.  Lancet. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9PubMedGoogle Scholar
12.
Bally  M, Dendukuri  N, Rich  B,  et al.  Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.  BMJ. 2017;357:j1909. doi:10.1136/bmj.j1909PubMedGoogle Scholar
13.
Thybo  KH, Hägi-Pedersen  D, Wetterslev  J,  et al.  PANSAID—paracetamol and NSAID in combination: study protocol for a randomised trial.  Trials. 2017;18(1):11. doi:10.1186/s13063-016-1749-7PubMedGoogle Scholar
14.
International Conference on Harmonisation Expert Working Group.  International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH harmonised tripartite guideline. Guideline for Good Clinical Practice E6 (R1). June 10. 1996.https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed January 19, 2019.
15.
Thybo  KH, Jakobsen  JC, Hägi-Pedersen  D,  et al.  PANSAID-paracetamol and NSAID in combination: detailed statistical analysis plan for a randomised, blinded, parallel, four-group multicentre clinical trial.  Trials. 2017;18(1):465. doi:10.1186/s13063-017-2203-1PubMedGoogle Scholar
16.
Chan  AW, Tetzlaff  JM, Altman  DG,  et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials.  Ann Intern Med. 2013;158(3):200-207. doi:10.7326/0003-4819-158-3-201302050-00583PubMedGoogle Scholar
17.
Schulz  KF, Altman  DG, Moher  D; CONSORT Group.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.  BMJ. 2010;340:c332. doi:10.1136/bmj.c332PubMedGoogle Scholar
18.
International Conference on Harmonisation Expert Working Group.  International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. October 27, 1994.https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf. Accessed May 17, 2018.
19.
Cao  J, Zhang  S.  Multiple comparison procedures.  JAMA. 2014;312(5):543-544. doi:10.1001/jama.2014.9440PubMedGoogle Scholar
20.
McGlothlin  AE, Lewis  RJ.  Minimal clinically important difference: defining what really matters to patients.  JAMA. 2014;312(13):1342-1343. doi:10.1001/jama.2014.13128PubMedGoogle Scholar
21.
Qu  Y, Zhao  YD, Rahardja  D.  Wilcoxon-Mann-Whitney test: stratify or not?  J Biopharm Stat. 2008;18(6):1103-1111. doi:10.1080/10543400802369103PubMedGoogle Scholar
22.
Kahan  BC, Morris  TP.  Improper analysis of trials randomised using stratified blocks or minimisation.  Stat Med. 2012;31(4):328-340. doi:10.1002/sim.4431PubMedGoogle Scholar
23.
Kahan  BC, Harhay  MO.  Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs.  J Clin Epidemiol. 2015;68(12):1504-1511. doi:10.1016/j.jclinepi.2015.03.016PubMedGoogle Scholar
24.
STATA.  Longitudinal-Data/Panal-Data Reference Manual.http://www.stata.com/bookstore/longitudinal-panel-data-reference-manual/. Accessed January 19, 2019.
25.
Jakobsen  JC, Gluud  C, Wetterslev  J, Winkel  P.  When and how should multiple imputation be used for handling missing data in randomised clinical trials—a practical guide with flowcharts.  BMC Med Res Methodol. 2017;17(1):162. doi:10.1186/s12874-017-0442-1PubMedGoogle Scholar
26.
Gomes  T, Tadrous  M, Mamdani  MM, Paterson  JM, Juurlink  DN.  The burden of opioid-related mortality in the United States.  JAMA Netw Open. 2018;1(2):e180217. doi:10.1001/jamanetworkopen.2018.0217PubMedGoogle Scholar
27.
Johnson  SP, Chung  KC, Zhong  L,  et al.  Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures.  J Hand Surg Am. 2016;41(10):947-957.e3. doi:10.1016/j.jhsa.2016.07.113PubMedGoogle Scholar
28.
Martinez  V, Beloeil  H, Marret  E, Fletcher  D, Ravaud  P, Trinquart  L.  Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials.  Br J Anaesth. 2017;118(1):22-31. doi:10.1093/bja/aew391PubMedGoogle Scholar
29.
Derry  CJ, Derry  S, Moore  RA.  Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain.  Cochrane Database Syst Rev. 2013;6(6):CD010210.PubMedGoogle Scholar
30.
Fabritius  ML, Mathiesen  O, Wetterslev  J, Dahl  JB.  Post-operative analgesia: focus has been on benefit—are we forgetting the harm?  Acta Anaesthesiol Scand. 2016;60(7):839-841. doi:10.1111/aas.12729PubMedGoogle Scholar
31.
Cuervo  LG, Clarke  M.  Balancing benefits and harms in health care.  BMJ. 2003;327(7406):65-66. doi:10.1136/bmj.327.7406.65PubMedGoogle Scholar
32.
O’Connor  D, Green  S, Higgins  JPT. Chapter 5. Defining the review question and developing criteria for including studies. In: Higgins  JPT, Green  S, eds.  Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. London, England: Cochrane Collaboration;2011.
33.
Ong  CK, Seymour  RA, Lirk  P, Merry  AF.  Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain.  Anesth Analg. 2010;110(4):1170-1179. doi:10.1213/ANE.0b013e3181cf9281PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close